T1	Participants 14 51	irresectable hepatocellular carcinoma
T2	Participants 97 177	A joint clinical prospective study between SUMS and Lund university was reported
T3	Participants 179 399	40 patients with the irresectable hepatocellular carcinoma (HCC) admitted to the department of HPB surgery in the First Affiliated Hospital of SUMS were randomized into two groups: (20 each) from Feb. 1994 to April, 1995
